190 related articles for article (PubMed ID: 17125403)
1. High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
Faller B; Wang J; Zimmerlin A; Bell L; Hamon J; Whitebread S; Azzaoui K; Bojanic D; Urban L
Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):823-33. PubMed ID: 17125403
[TBL] [Abstract][Full Text] [Related]
2. Metabolite identification and profiling in drug design: current practice and future directions.
Zhang Z; Zhu M; Tang W
Curr Pharm Des; 2009; 15(19):2220-35. PubMed ID: 19601824
[TBL] [Abstract][Full Text] [Related]
3. Drug-like property concepts in pharmaceutical design.
Di L; Kerns EH; Carter GT
Curr Pharm Des; 2009; 15(19):2184-94. PubMed ID: 19601822
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450s and other enzymes in drug metabolism and toxicity.
Guengerich FP
AAPS J; 2006 Mar; 8(1):E101-11. PubMed ID: 16584116
[TBL] [Abstract][Full Text] [Related]
5. A hierarchical screening methodology for physicochemical/ADME/Tox profiling.
DeWitte RS; Robins RH
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):805-17. PubMed ID: 17014396
[TBL] [Abstract][Full Text] [Related]
6. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
7. Successful drug discovery.
Swinney DC
Curr Top Med Chem; 2006; 6(5):403-4. PubMed ID: 16719799
[No Abstract] [Full Text] [Related]
8. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
9. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
Yan Z; Caldwell GW
Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
[TBL] [Abstract][Full Text] [Related]
10. In silico prediction of cytochrome P450-mediated drug metabolism.
Zhang T; Chen Q; Li L; Liu LA; Wei DQ
Comb Chem High Throughput Screen; 2011 Jun; 14(5):388-95. PubMed ID: 21470181
[TBL] [Abstract][Full Text] [Related]
11. Fundamental problems lie ahead in the drug discovery and commercialization process: restructuring of the pharmaceutical industry and an improved partnership with academia are required.
Brewer GJ
J Investig Med; 2006 Sep; 54(6):291-302. PubMed ID: 17191351
[No Abstract] [Full Text] [Related]
12. ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.
Gleeson P; Bravi G; Modi S; Lowe D
Bioorg Med Chem; 2009 Aug; 17(16):5906-19. PubMed ID: 19632124
[TBL] [Abstract][Full Text] [Related]
13. Biosensor profiling of molecular interactions in pharmacology.
Cooper MA
Curr Opin Pharmacol; 2003 Oct; 3(5):557-62. PubMed ID: 14559103
[TBL] [Abstract][Full Text] [Related]
14. Systems biology in drug safety and metabolism: integration of microarray, real-time PCR and enzyme approaches.
Yengi LG
Pharmacogenomics; 2005 Mar; 6(2):185-92. PubMed ID: 15882137
[TBL] [Abstract][Full Text] [Related]
15. Synthetic peptide API manufacturing: A mini review of current perspectives for peptide manufacturing.
Rasmussen JH
Bioorg Med Chem; 2018 Jun; 26(10):2914-2918. PubMed ID: 29735426
[No Abstract] [Full Text] [Related]
16. In vitro methods to assess drug precipitation.
Dai WG
Int J Pharm; 2010 Jun; 393(1-2):1-16. PubMed ID: 20347943
[TBL] [Abstract][Full Text] [Related]
17. Organic chemistry in drug discovery.
MacCoss M; Baillie TA
Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494
[TBL] [Abstract][Full Text] [Related]
18. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
19. Use of in vitro human metabolism studies in drug development. An industrial perspective.
Rodrigues AD
Biochem Pharmacol; 1994 Dec; 48(12):2147-56. PubMed ID: 7811296
[No Abstract] [Full Text] [Related]
20. Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department.
Sohlenius-Sternbeck AK; Janson J; Bylund J; Baranczewski P; Breitholtz-Emanuelsson A; Hu Y; Tsoi C; Lindgren A; Gissberg O; Bueters T; Briem S; Juric S; Johansson J; Bergh M; Hoogstraate J
Curr Drug Metab; 2016; 17(3):253-70. PubMed ID: 26651977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
